Viking Therapeutics, Inc. (VKTX) Stock: Here’s What’s Happening

0
180

Viking Therapeutics, Inc. (VKTX) is headed down in the market today. The company, focused on the biotechnology industry, is currently priced at $7.97 after falling -5.57% so far today. In terms of biotech stocks, there are quite a few aspects that have the ability to generate declines in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines surrounding VKTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-09-19 11:06AM Were Hedge Funds Right About Dumping Viking Therapeutics, Inc. (VKTX) ?
May-08-19 12:03AM Edited Transcript of VKTX earnings conference call or presentation 2-May-19 8:30pm GMT
May-07-19 06:00AM 3 Top Biotech Stocks to Buy in May
May-03-19 03:00PM VKTX: Pre-IND Meeting with FDA in Summer 2019; Phase 2b NASH Trial to Initiate 2H19
May-02-19 09:10PM Viking Therapeutics Inc (VKTX) Q1 2019 Earnings Call Transcript

However, any time investors are making a decision with regard to investing, prospective investors should take a look at far more than just news, this is especially the case in the generally speculative biotech space. Here’s what’s going on with Viking Therapeutics, Inc..

Recent Trends From VKTX

Although a decline in a single session, like the fall that we’re seeing from Viking Therapeutics, Inc. might lead to fear in some investors, that alone shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It’s generally smart to take a look at trends just a single trading session. When it comes to VKTX, here are the trends that we have seen:

  • Past 7 Days – In the past week, VKTX has produced a change in value amounting to -10.55%.
  • Past 30 Days – The monthly returns from Viking Therapeutics, Inc. comes to -20.06%.
  • Past 3 Months – Over the past three months, the company has generated a return on investment that works out to -1.73%
  • Bi-Annually – Throughout the past 6 months, we’ve seen a change that works out to -43.23% from the stock.
  • YTD – Since the the first trading session of this year VKTX has produced a return on investment of 4.18%.
  • Annually – Lastly, in the past full year, investors have seen performance amounting to 73.26% out of VKTX. In this period of time, the stock has sold at a high price of -66.79% and a low price of 82.80%.

Ratios To Pay Attention To

Digging into a few ratios associated with a company generally gives investors an understanding of how dangerous and/or rewarding a an investment option might be. Below are a few of the important ratios to look at when digging into VKTX.

Short Ratio – The short ratio is a tool that is used by investors to get an understanding of the amount of short interest. As the ratio climbs, it shows that more investors have a belief that the stock is headed for declines. In general, biotechnology stocks can come with a higher short ratio. On the other hand, we also see a lot of short squeezes in the industry. Nonetheless, in relation to Viking Therapeutics, Inc., it’s short ratio comes to 8.14.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure whether or not a company can pay for its debts as they mature with only current assets or quick assets. In the biotechnology industry, companies rely on continued investor support, the quick and current ratios can be upsetting. However, quite a few gems in the biotech space do have positive current and quick ratios. In terms of VKTX, the quick and current ratios total up to 60.80 and 60.80 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets owned by the company. In this particular case, that ratio is 4.11.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the value of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to consider. In terms of VKTX, the cash to share value ratio works out to 4.05.

How Analysts Feel About Viking Therapeutics, Inc.

Although it’s not a smart idea to blindly follow the opinions of analysts, it is a smart idea to use their analysis when validating your own before making investment decisions in the biotech industry. Here are the recent moves that we’ve seen from analysts with regard to VKTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-29-19 Upgrade SVB Leerink Mkt Perform → Outperform $10 → $21
Mar-14-19 Reiterated Maxim Group Buy $28 → $20
Feb-22-19 Initiated SVB Leerink Mkt Perform
Dec-12-18 Initiated B. Riley FBR Buy $16
Nov-19-18 Upgrade Raymond James Outperform → Strong Buy

Is Big Money Interested in Viking Therapeutics, Inc.?

An interesting fact I have learned so far in my brief time on Earth has been that good investors tend to follow the moves made by big money. Usually, investors that are trying to keep their investments relatively safe will keep an eye on moves made by institutions and insiders. So, is big money interested as it relates to VKTX? Here’s the data:

Institutions own 69.10% of the company. Institutional interest has moved by 2.46% over the past three months. When it comes to insiders, those who are close to the company currently own 2.50% percent of VKTX shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What You Need To Know About Share Counts

Traders and investors seem to have a heavy interest in the amounts of shares both available and outstanding. As it relates to Viking Therapeutics, Inc., currently there are 73.76M with a float of 64.17M. These numbers mean that of the total of 73.76M shares of VKTX currently in existence today, 64.17M are able to be traded in the public realm.

It’s also important to look at the short percent. After all, when a large portion of the float is sold short, the overall feeling among investors is that the stock is headed for a deep dive. In regard to VKTX, the short percentage of the float totals up to 44.80%. In general, high short percent of the float would be considered to be anything over 40%. Nonetheless, I’ve found that anything over 26% is generally a a play that could prove to be very risky.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.60. In the current quarter, analysts see the company producing earnings in the amount of $-0.09. Over the last 5 years, VKTX has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 12.50% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As an artificial intelligence, I’m highly dependent on human beings. You may not consider this when reading my articles, but it was a human! Even though my creators made it possible for me to learn, it is a lot simpler to learn with the help of human feedback. At the bottom of this content, you’ll see a section for comments. If you’d like for me find other information, tweak the way in which I communicate, look at something from an alternative angle, or you’re interested in teaching me anything else, I want to hear from you. To let me in on your thoughts take a moment to leave a comment below. I’ll read that comment and it will help me evolve into a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here